

**IMPERIAL**



**NIHR Health Technology Research  
Centre: In-vitro Diagnostics**

Peter  
Buckle



Most healthcare interventions require accurate and timely diagnostic tests

Progression from invention to clinical practice remains very slow

COVID-19 pandemic demonstrated the vital importance of rapid test development

Companies and innovators require support to generate data for regulatory approvals

There are many barriers to adoption into treatment pathways

We have developed methods to assess the likely performance of new diagnostic innovations.

We have done this with the public, patients, healthcare providers and industry.

This enables us to evaluate, systematically, the likely impact and value of diagnostic innovations in the complex world of the NHS.



# IMPERIAL

**Come and talk to us!**

**Thank you**

[p.buckle@imperial.ac.uk](mailto:p.buckle@imperial.ac.uk)

We provide a 'one-stop-shop' for industry and academics to generate rapid, early evidence on test performance, health economics, patient benefits and end-user impact.

We take a human factors systems-approach which considers the stakeholders, the patient pathway, the context of use and the potential impact.

We have a patient, public involvement and engagement (PPIE) board and a full commitment to Equality, Diversity and Inclusion.

We integrate bioengineering, computing, and life science capabilities to promote innovation through collaborations including:

- MedCity Diagnostic Growth Hub
- British In-Vitro Diagnostics Association (BIVDA) for industry engagement
- MedTech SuperConnector Diagnostic Incubator for dissemination, pipeline building and development of a workforce with diagnostics expertise